aTyr Pharma has aligned with the FDA on a Phase Three efzofitimod study using 5.0 mg/kg intravenous dosing every 3 weeks for patients with pulmonary sarcoidosis and restrictive lung disease. The plan matters to investors because U.S. and European submissions are targeted while future development will require additional capital.
Key Highlights
- The planned trial will keep participants’ background treatments stable throughout the study.
- Forced vital capacity change at week 48 will serve as the primary endpoint.
- ATYR expects to begin study activities in the fourth quarter of 2026.
- Efzofitimod will be evaluated in a randomized, double-blind, placebo-controlled global study for moderate to severe pulmonary sarcoidosis.
ATYR (NASDAQ: ATYR) is a major pharmaceuticals company. The company expects to begin study activities in the fourth quarter of 2026 while focusing on regulatory submissions in the United States and Europe.
Efzofitimod Study Sets 5.0 mg/kg Regimen
The global study will be randomized, double-blind, placebo-controlled and designed to evaluate efzofitimod’s efficacy and safety in moderate to severe pulmonary sarcoidosis. Participants will be assigned equally to efzofitimod or placebo, with efzofitimod administered intravenously at 5.0 mg/kg once every 3 weeks. The planned population includes patients receiving a stable oral corticosteroid dose of ≤ 5.0 mg daily and/or a background immunosuppressant. The protocol calls for forced vital capacity change from baseline at week 48 as the primary endpoint and the KSQ-Lung score as the key secondary endpoint.
Future Development Requires Additional Capital
The company also identified risks involving patient enrollment, FDA interactions, future study results and its ability to raise the required funding.
FAQs
Q: What dose will efzofitimod use in aTyr Pharma’s planned study?
A: The protocol calls for 5.0 mg/kg of efzofitimod given intravenously once every 3 weeks. Participants will be assigned to efzofitimod or placebo.
Q: What is aTyr Pharma’s primary endpoint for the efzofitimod study?
A: The primary endpoint is the change from baseline in forced vital capacity at week 48. Change in the KSQ-Lung score at week 48 is the key secondary endpoint.
Q: How will aTyr Pharma fund future efzofitimod development?
A: Future efzofitimod development will require additional capital. The company identifies its ability to raise the required funding as a risk.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.